NextGenNK is a Vinnova initiated competence center, launched in 2020, for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. XNK Therapeutics collaborate within this competence center to perform an open, randomized, controlled phase II trial with autologous NK cells (CellProtect) in combination with anti-CD38 antibody in patients with multiple myeloma (MM)

The Competence Centre for Advanced BioProduction by Continuous Processing, AdBIOPRO, aims at developing competitive technology for bioproduction, focusing on the imminent paradigm shift towards continuous processes of biopharmaceuticals, and on manufacturing of emerging potent therapeutic products such as recombinant viral vector and cell products. XNK Therapeutics collaborate within this competence centre to established manufacturing protocol to enable production of CellProtect in Sweden supporting confirmatory clinical studies. The work addresses biological factors governing a product of high quality.  

Swelife-ATMP is a project within the strategic innovation program Swelife, a common investment of Vinnova, Formas and the Swedish Energy Agency. Swelife-ATMP focuses on development of the knowledge, processes, competencies and support functions required to take an ATMP from the preclinical stage to the patient. This involves identifying ATMP specific gaps in law, ethics and regulation, as well as identifying specific needs within healthcare, business, research and industry. XNK Therapeutics collaborate within this innovation program in a project WHICH focuses on business development based on health economics data,  value-based health care and pricing infrastructures FURTHERMOST within Sweden. The aim is to identify opportunities and threats for advanced therapy medicinal products (ATMP) to reach the use in clinical practice for the benefits of the patients.